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Roy K. Greenberg, Timothy A.M. Chuter, Richard P. Cambria, W. Charles
Sternbergh, Neal E. Fearnot
Purpose: The safety and efficacy of the Zenith (Cook Inc, Bloomington, Ind)
endovascular graft was assessed based on the United States multicenter trial
through 5 years of follow-up
Methods: Between 2000 and 2003, the pivotal study enrolled patients to
open surgery (control) or the Zenith endovascular graft (endovascular). A
separate continued access study arm enrolled endovascular patients using
the same inclusion/exclusion criteria. Both studies were designed for 2-year
follow-up, and the pivotal endovascular patients had the option of extending
the study follow-up through 5 years. All endovascular patients were strati-
fied by physiologic risk into high-risk and standard-risk groups to assess over-
all mortality, rupture, conversion, endoleaks, secondary interventions, and
sac enlargement. The entire endovascular cohort was pooled to assess de-
vice integrity, limb occlusion, component separation, and migration. The
suboptimal endovascular end point (SER) was established as an end point
to assess late adverse outcomes. Statistical analyses included Kaplan-Meier
estimations and Cox regression to assess factors contributing to sac enlarge-
ment and SER.
Results: The study enrolled 739 endovascular patients (352 pivotal, 287 con-
tinued access); 158 patients in the pivotal study reconsented to be followed
up for 5 years. For the patients at standard and high risk at 5 years, the re-
spective survival estimate was 83% and 61%, aneurysm-related death was 2%
and 4%, and freedom from rupture was 100% and 99.6%, respectively. Cumu-
lative risk of conversion, limb occlusion, migration >10 mm, or component
separation was 3% at 5 years. Cumulative risk of late endoleak was 12%
to 15%, representing the primary indication for secondary interventions
which occurred in 20% of standard-risk patients and 25% of high-risk patients
through 5 years. Sac enlargement was very rare and associated with ad-
vanced age and larger aneurysms. SER was predicted by advanced age and
internal iliac artery occlusion.
Conclusion: These middle- and long-term data support long-term durability
of the Zenith endovascular graft. Risk of aneurysm-related death or rupture
was exceptionally low, and complications of migration, limb occlusion, and
device integrity issues were uncommon. Incidence of late endoleaks and as-
sociation of endoleaks with sac growth underscore the need for long-term
follow-up of patients treated with endovascular grafts, although the
sequelae of such events are unknown.Contemporary results of open repair of ruptured abdominal aorto-iliac
aneurysms: Effect of surgeon volume on mortality
Jae-Sung Cho, Jang Yong Kim, Robert Y. Rhee, NavYash Gupta, Luke K.
Marone, Ellen D. Dillavou, Michel S. Makaroun
Objective: The purpose of this study is to evaluate contemporary results of
ruptured aortoiliac aneurysms (RAAA) and identify the role of surgeons’ an-
nual aortic volume and other prognostic indicators for early outcome.
Methods: A retrospective review identified 213 consecutive patients who
presented with an atherosclerotic RAAA without thoracic extension over
6.5 years ending in June 2007. Excluded were 31 ruptures treated by* Full articles available online at www.jvascsurg.org
1078e5884/$34.00
doi:10.1016/S1078-5884(08)00265-7endovascular repair (EVAR) or following previous EVAR, also excluded were
two chronic asymptomatic hemodynamically stable ruptures. Ten patients
were not treated due to either patient’s refusal or prohibitive surgical risk.
Demographic, preoperative, intraoperative, and postoperative variables
were collected. Log rank test and Cox proportional hazard model analyses
were utilized to identify factors contributing to mortality and morbidity in
these patients. Survival rates were estimated by Kaplan-Meier method.
Results: One hundred thirty-one males and 39 females with a mean age of
74.5  8.1 years underwent consecutive RAAA repairs. The operative mortal-
ity rate was 38.2% (65/170), including 29 intraoperative deaths. Using multi-
variate analysis, surgeon’s average annual AAA volume (<20/y), advanced
age, and postoperative intestinal ischemia were independent predictors of
perioperative deaths. Shock on presentation, preoperative cardiopulmonary
resuscitation or free rupture were not. High-volume surgeons (>20 average
annual AAA cases/y) had a higher 30-day survival rates (78.4% vs 57.9%,
P = .024). Octogenarians had a lower 30-day survival rate of 49.0% vs
70.5% (P = .012). Patients who developed postoperative intestinal ischemia
had a lower 30-day survival rate compared with patients without (48.1% vs
15.3%, P = .002). Increased intraoperative fluid and blood product usage
was associated with bowel ischemia (P < .05).
Conclusions: RAAA remains a highly lethal problem. The improved early out-
comes of surgeons with high-volume AAA have strong implications for train-
ing, emergency staffing needs and alternative treatment strategies.Spinal cord complications after thoracic aortic surgery: Long-term
survival and functional status varies with deficit severity
Mark F. Conrad, Jason Y. Ye, Thomas K. Chung, J. Kenneth Davison, Richard
P. Cambria
Objective: Paraplegia after thoracoabdominal aneurysm (TAA) repair has
been associated with poor survival. Little information exists concerning
the spectrum of severity that characterizes spinal cord ischemic (SCI) com-
plications. This study stratified SCI by deficit severity to determine its im-
pact on late survival and functional outcomes.
Methods: A review of our prospectively maintained thoracic aortic database
was performed from May 1987 through December 2005 to identify patients
who experienced SCI of any extent after TAA repair. During this period,
576 patients underwent descending thoracic aortic repair (93 open, 105 en-
dovascular [TEVAR]) or open TAA repair (279 extent I to III; 99 extent IV). To
stratify severity of SCI, we created a spinal cord ischemia deficit (SCID)
scale, which is defined as: I, flaccid paralysis; II, average neurologic muscle
grade indicating <50% function; and III, average neurologic muscle grade in-
dicating >50% function. Long-term outcomes were evaluated in relation to
these groups by actuarial methods.
Results: During the study period, 64 (11.1%) patients developed SCI of any
severity (7 of 105 [6.6%] TEVAR, 57 of 471 [12%] open). These were stratified
by SCID level: I, 24 (37.5%); II, 31 (48.4%); and III, 9 (14.1%). SCI was imme-
diate in 33 (54.1%) and delayed in 28 (45.9%). Most SCI (6 of 7) associated
with TEVAR was delayed. The 30-day mortality was significantly higher in
the SCI group than the overall patient cohort (15 of 64 [23.4%] vs 41 of
512 [8%], P < .001) and varied by SCID level: I, 11 of 24 (45.8%); II, 4 of 31
(12.9%); and III, 0 of 9 (0%; P = .001). The 5-year actuarial survival for all
SCI was lower than for non-SCI patients (25%  6% vs 51%  3%, P < .001)
and varied linearly with SCID level but was similar between SCID II/III and
the non-SCI patients (41%  10% vs 51%  3%, P = .281). No SCID I patients
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but eight of 11 (73%) with SCID II and the nine (100%) with SCID III could
ambulate with or without assistance at last follow-up.
Conclusion: Survival and functional outcomes correlate with SCI severity.
Patients with SCID I have a poor long-term outlook. Survival of SCID II/III pa-
tients is similar to non-SCI patients; most recover the ability to ambulate.Carotid artery stenting: Identification of risk factors for poor outcomes
Benjamin M. Jackson, Sean J. English, Ronald M. Fairman, Jagajan
Karmacharya, Jeffrey P. Carpenter, Edward Y. Woo
Objectives: Age greater than 80 has been identified as a risk factor for com-
plications, including stroke and death, in patients undergoing carotid artery
angioplasty and stenting (CAS). This study evaluates other potential predic-
tors of perioperative complications in patients undergoing CAS.
Methods: All cerebrovascular endovascular procedures performed by the
vascular surgery division at our university hospital between July 2003 and
December 2005 were retrospectively examined. During the course of 212 ad-
missions, 198 patients underwent 215 procedures. Patient age, comorbid-
ities, and admission status were analyzed as independent (predictor)
variables. Complication rate, discharge disposition, and length of hospital
stay were considered dependent (outcome) variables. Logistic regression
and Fisher exact test or Student t test were performed, as appropriate.
Results: Complications included major and minor stroke, myocardial infarc-
tion, femoral artery pseudoaneurysm, and death. The rates of perioperative
major and minor stroke were 0.5% and 2.8%, respectively. Chronic renal in-
sufficiency was a predictor of perioperative complications, including stroke:
patients with serum creatinine greater than 1.3 mg/dL had a 37% complica-
tion rate and a 11.1% stroke rate, while those with normal renal function had
a 13% complication rate (P = .003) and a 0.6% stroke rate (P =.001). Similar
association was seen between creatinine clearance and both stroke and
complications. Obesity was a risk factor for complications, but not stroke:
obese patients had a complication rate of 28%, while others had a 16% com-
plication rate (P = .024). Emergency admission predicted both extended
hospital stay (P < .001) and requirement for further inpatient care in a reha-
bilitation or nursing facility (P = .007). There was no significant difference in
complication rate or stroke rate between octogenarians and others.
Conclusion: This experience demonstrates that chronic renal insufficiency,
obesity, and emergent clinical setting are risk factors for patients under-
going CAS.Infrapopliteal angioplasty for critical limb ischemia: Relation of
TransAtlantic InterSociety Consensus class to outcome in 176 limbs
Kristina A. Giles, Frank B. Pomposelli, Allen D. Hamdan, Seth B. Blattman,
Haig Panossian, Marc L. Schermerhorn
Objective: Recent data suggest that percutaneous transluminal angioplasty
(PTA) may be appropriate primary therapy for critical limb ischemia (CLI).
However, little data are available regarding infrapopliteal angioplasty out-
comes based on TransAtlantic InterSociety Consensus (TASC) classification.
We report our experience with infrapopliteal angioplasty stratified by TASC
lesion classification.
Methods: From February 2004 to March 2007, 176 consecutive limbs (163 pa-
tients) underwent infrapopliteal angioplasty for CLI. Stents were placed for
lesions refractory to PTA or flow-limiting dissections. Patients were stratified
by TASC classification and suitability for bypass grafting. Primary outcome
was freedom from restenosis, reintervention, or amputation. Primary pa-
tency, freedom from secondary restenosis, limb salvage, reintervention by
repeat angioplasty or bypass, and survival were determined.
Results: Median agewas 73 years (range, 39e94 years). Technical success was
93%. Average follow-up was 10 months (range, 1-41 months). At 1 and 2 years,
freedom from restenosis, reintervention, or amputation was 39% and 35%,
conventional primary patency was 53% and 51%, and freedom from secondary
restenosis and reintervention were 63% and 61%, respectively. Limb salvage
was 84% at 1, 2, and 3 years. Within 2 years, 15% underwent bypass and 18%
underwent repeat infrapopliteal PTA. Postoperative complications occurred
in 9% and intraprocedural complications in 10%. The 30-day mortality was 5%
(9 of 181). Overall survival was 81%, 65%, and 54% at 1, 2, and 3 years. TASC
D classification predicted diminished technical success (75% D vs 100% A, B,
and C; P < .001), primary restenosis, reintervention, or amputation (hazard
ratio [HR], 3.4; 95% confidence interval [CI], 2.1-5.5, P < .001), primary pa-
tency (HR, 2.2; 95% CI, 1.3-3.9, P < .004), secondary restenosis (HR, 3.2;95% CI, 1.6-6.4, P = .001), and limb salvage (HR, 2.6; 95% CI, 1.1-6.3, P <
.05). Unsuitability for surgical bypass also predicted restenosis, reinterven-
tion, or amputation, secondary restenosis, need for repeated angioplasty,
and inferior primary patency and limb salvage rates.
Conclusion: Infrapopliteal angioplasty is a reasonable primary treatment for
CLI patients with TASC A, B, or C lesions. Restenosis, reintervention, or ampu-
tation was higher in patients who were unsuitable candidates for bypass;
however, an attempt at PTAmay be indicated as an alternative to primary am-
putation. Although restenosis, reintervention, or amputation is high after tib-
ial angioplasty for CLI, excellent limb salvage rates may be obtained with
careful follow-upand reinterventionswhennecessary, includingbypass in 15%.Peroneal artery-only runoff following endovascular revascularizations is
effective for limb salvage in patients with tissue loss
Hasan H. Dosluoglu, Gregory S. Cherr, Purandath Lall, Linda M. Harris,
Maciej L. Dryjski
Objective: Peroneal artery bypass is effective for limb salvage (LS), how-
ever, the efficacy of peroneal artery-only runoff (PAOR) following endo-
vascular (EV) interventions is unknown. The goal of our article was to
compare the efficacy of EV interventions with PAOR to those with other
runoff vessels for LS in patients presenting with tissue loss.
Methods: A retrospective review of 111 consecutive patients who under-
went infrainguinal EV revascularizations for nonhealing ulcers/gangrene be-
tween June 2001 and December 2006 was performed. Patients with PAOR (n
= 33) were compared with those with other vessel runoff (OTHER, n = 78).
Fisher exact test and c2 test were used for comparing variables, Kaplan-
Meier analyses for patency, LS, and Cox regression multivariate analysis
was used for identifying factors associated with limb loss.
Results: The patients in PAOR were older, but other morbidities were similar
between groups. The most distal level of intervention was infrapopliteal
(tibioperoneal or peroneal artery) in 42% in PAOR group whereas this was 24%
in OTHER group (P = .071). Preoperative ankle-brachial index (ABI) was similar
(0.49 0.23 vs 0.50 0.23), however, postprocedure ABI was significantly less
for patients with PAOR (0.76  0.21 vs 0.92  0.13, P = .001). The primary
patency, assisted primary patency, secondary patency and LS were not signif-
icantly different between groups. There was also no difference in time-to
healing between groups (PAOR vs OTHER, 2.9  2.1 mo vs 3.7  3.6 mo, P =
.319).We found thepresenceof gangrene (odds ratio [OR]: 3.5, 95%confidence
interval [CI], 1.1-10.8, P = .028) and dialysis-dependence (OR: 2.9, 95% CI,
1.0-8.2, P = .046) to be associated with limb loss, when adjusted for diabetes,
hypertension, hyperlipidemia, smoking, location of wound, and PAOR.
Conclusion: Endovascular revascularization with PAOR results in acceptable
patency and limb salvage rates in patients presenting with tissue loss, and is
equivalent to other vessel runoff for patency, limb salvage and wound heal-
ing rates.Subscapular artery Y-shaped flow-through muscle flap: A novel one-stage
limb salvage procedure
Sergueı¨ Malikov, Pierre-Edouard Magnan, Pierre Champsaur, Dominique
Casanova, Alain Branchereau
Objectives: Major tissue loss caused by the critical limb ischemia requires
improvement of distal perfusion and cover of large tissue defects. We pro-
pose a new method, the Y-shaped subscapular artery flow-through (Y-SCAFT)
muscle flap using the subscapular artery that yields an arterial graft and
a free muscle flap sustained by a collateral branch of this artery. This pro-
spective study evaluated the feasibility of this technique and analyzed
wound healing, graft patency, and limb salvage.
Methods: Between 2002 and 2007, 20 patients, mean age 64 years (range,
55e79 years), were treated with this technique. All presented with critical
ischemia and major tissue loss, with exposure of the tendons, bones, or
joint, and were candidates for major amputation. Revascularization and
cover of tissue loss with the same Y-SCAFT anatomic unit was used for all pa-
tients. The distal anastomosis was performed between the distal branch of
the Y-SCAFT and the pedal artery in 9, posterior tibial artery in 4, peroneal
artery in 1, lateral tarsal artery in 3, and the plantar artery in 3. In four pa-
tients, the distal part of the arterial graft, including the anastomosis, was
covered with the muscle flap because the tissue loss was nearby. The prox-
imal anastomosis was performed between a leg artery and the arterial graft
in 10 patients. A venous graft was necessary in 10 patients to extend the by-
pass proximally.
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evidenced patency all the Y-SCAFT muscle flaps. Healing was achieved in
all patients. Mean follow-up was 31 months (range, 6-58 months). No pa-
tients died during follow-up. One patient presented occlusion of the Y-SCAFT
muscle flap and underwent amputated. One patient had major amputation
despite a patent graft. At 2 years, leg salvage was 85%, patency was 94%,
and survival was 94%. At the end of the follow-up, 17 patients (1 death, 2
amputations) had a patent graft, a viable muscle flap, wound healing, and
a functional leg.
Conclusion: We showed the clinical feasibility of the technique of Y-SCAFT
muscle flap, which allows for revascularization and cover of major tissue loss
with one anatomic unit. This method is particularly useful in selected cases
with poor run-off and large ischemic lesions.Endovenous laser ablation (EVLA): Does standard above-knee great
saphenous vein ablation provide optimum results in patients with both
above and below knee reflux? A randomized controlled trial
Nadarajah S. Theivacumar, Demos Dellagrammaticas, Andrew I.D. Mavor,
Michael J. GoughBackground: Following above-knee (AK) great saphenous vein (GSV)
endovenous laser ablation (EVLA) 40% to 50% patients have residual varicosi-
ties. This randomized controlled trial (RCT) assesses whether more extensive
GSV ablation enhances their resolution and influences symptom improvement.
Method: Sixty-eight limbs (65 patients) with varicosities and above and
below-knee GSV reflux were randomized to Group A: AK-EVLA (n = 23); Group
B: EVLA mid-calf to groin (n = 23); and Group C: AK-EVLA, concomitant be-
low-knee GSV foam sclerotherapy (n = 22). Primary outcomes were residual
varicosities requiring sclerotherapy (6 weeks), improvement in Aberdeen
varicose vein severity scores (AVVSS, 12 weeks), patient satisfaction, and
complication rates.
Results: EVLA ablated the treated GSV in all limbs. Sclerotherapy require-
ments were Group A: 14/23 (61%); Group B: 4/23 (17%); and Group C: 8/22
(36%); X2 = 9.3 (2 df) P = .01 with PA-B = 0.006; PB-C = 0.19; PA-C = 0.14. AVVSS
scores improved in all groups as follows: A: 14.8 (9.3-22.6) to 6.4 (3.2-9.1),
(P < .001); B: 15.8 (10.2-24.5) to 2.5 (1.1-3.7), (P < .001); and C: 15.1 (9.0-
23.1) to 4.1 (2.3-6.8), (P < .001) and PA-B = 0.011, PA -C = 0.042. Patient sat-
isfaction was highest in Group B. BK-EVLA was not associated with saphenous
nerve injury.
Conclusions: Extended EVLA is safe, increases spontaneous resolution of
varicosities, and has a greater impact on symptom reduction. Similar bene-
fits occurred after concomitant BK-GSV foam sclerotherapy.
